BIOMARIN PHARMACEUTICAL INC Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of -$771.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was -$771.00K.
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was -$1.21M, a 142.69% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was $2.84M, a 212.79% increase from fiscal 2021.
- BIOMARIN PHARMACEUTICAL INC effective income tax rate reconciliation, other adjustments, amount for fiscal 2021 was $907.00K, a 50.79% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | -$771.00K 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$1.21M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $2.84M 10-K · filed 2025-02-24 | |
| 2021-12-31 | $907.00K 10-K · filed 2024-02-26 | |
| 2020-12-31 | $1.84M 10-K · filed 2023-02-27 | |
| 2019-12-31 | -$1.13M 10-K · filed 2022-02-25 | |
| 2018-12-31 | -$423.00K 10-K · filed 2021-02-26 | -$422.00K 10-K · filed 2019-02-28 |
| 2017-12-31 | -$2.94M 10-K · filed 2020-02-27 | -$2.94M 10-K · filed 2019-02-28 |
| 2016-12-31 | -$5.13M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |